x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

OncoPharm

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

science

All Episodes

00:15:27

Talking about cancer misinformation

OncoPharm ·

2025/05/22

If you've been struggling with how to talk to patients about ivermectin for cancer, then this podcast is for you.1. Cancer misinformation on social media (Loeb, et al): https://doi.org/10.3322/caac.21857 2. Clinician communication with patients about cancer misinformation (Bylund, et al): https://doi.org/10.1200/OP.22.00526

en

00:12:20

Four New Drugs

OncoPharm ·

2025/05/22

Discussing recent FDA approvals of penpulimab, avutometenib, defactinib, and telisotuzumab vedotin.

en

00:15:48

Mg to Prevent Cisplatin Kidney Injury

OncoPharm ·

2025/05/08

A splashy large study and two small studies suggest IV Mg in pre-hydration fluids can decrease the risk of cisplatin kidney injury.Gupta et al. JAMA Oncol (2025): doi:10.1001/jamaoncol.2025.0756 PRAGMATIC. ESMO Open (2022): https://doi.org/10.1016/j.esmoop.2021.100351 Yamamoto et al. Anticancer Res (2015): https://pubmed.ncbi.nlm.nih.gov/25862878/

en

00:12:11

TI-CH, Updates on dostarlimab, ventoclax, & zongertinib

OncoPharm ·

2025/05/01

This episode summarizes recent updates on:Tumor infiltrating clonal hematopoiesis (TI-CH) and its apparent negative impact on solid tumors (https://www.nejm.org/doi/full/10.1056/NEJMoa2413361) Updated dostarlimab data on MMRd use in rectal cancer and other solid tumors in the neoadjuvant (definitive?!?!) setting (https://www.nejm.org/doi/full/10.1056/NEJMoa2404512) Phase 1 study of 7 + 3 + Venetoclax (https://doi.org/10.1182/blood.2024026700) Zongertinib, a new HER2 TKI

en

00:12:43

BRCA Reversion Mutations

OncoPharm ·

2025/04/24

BRCA revision mutations may explain some of the limited benefit seen in long-term follow-up studies with PARP inhibitors.Bibliography: 1: BRCA reversion mutations predict resistance. https://doi.org/10.1158/2159-8290.CD-18-0715 2: SOLO3 Final OS Data. https://doi.org/10.1200/JCO.24.00933 3: Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. https://doi.org/10.1016/j.ccell.2024.10.015

en

00:11:45

HOPA 25 Recap

OncoPharm ·

2025/04/17

Recapping HOPA 25 and Portland*Great food (not discussed, the most excellent ETSU dinner at Arden) *COCOON *Pharmacists make everyone's job easier and keep patients out of the ED *A few more tidbits too!

en

00:12:25

Expanded Approvals for Durvalumab, Lu 177 vt;...

OncoPharm ·

2025/04/08

FDA expands approvals for durvalumab (bladder cancer) and Lutetium-177 vipivotide tetraxetan (pre-taxane in metastatic prostate cancer). Portland has places.

en

00:12:42

API-CAT & IMPROVE

OncoPharm ·

2025/04/03

We discuss reduced dose apixaban for months 6+ of treating cancer-associated VTE (API-CAT) and the impact (or lack thereof) of pausing BTK-inhibitors around vaccination (IMPROVE)

en

00:09:46

Topotecan

OncoPharm ·

2025/04/03

A Foundations of OncoPharm episode on Topotecan. (Originally to be released week of 3/27)

en

00:12:59

Keynote 811 Update

OncoPharm ·

2025/03/19

The updated Keynote 811 OS results convert an accelerated approval for pembrolizumab to a regular approval, albeit restricted by PD-L1 CPS status of 1 or higher.

en

00:09:59

Polar: Cryotherapy or Compression to Prevent...

OncoPharm ·

2025/03/13

There is a decent track record with mixed results for cryotherapy to prevent taxane-induced peripheral neuropathy. The POLAR trial adds to this body of evidence that trends in favor of cryotherapy. Compression therapy is another alternative. Both are studied in POLAR.POLAR: doi:10.1001/jamaoncol.2025.0001

en

00:11:48

About Herb Drug Interactions

OncoPharm ·

2025/03/06

Ten of the top herb-chemotherapy interactions.About Herbs website: https://www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine/herbs/search Also, search 'About Herbs' in your app store.

en

00:08:35

Rethinking Premeds

OncoPharm ·

2025/02/27

Two recent publications suggest modifications to standard subcutaneous daratumumab pre-meds is safe...and saves time!Padmaraju et al experience from Chicago Med Center: https://doi.org/10.1093/oncolo/oyae158 Vazirnia et al experience from Mayo Clinic: https://doi.org/10.1200/OP.23.00470 We end summarizing some emerging evidence about the need, or lack thereof, for pre-paclitaxel H2RAs.

en

00:17:25

AMPLIFY

OncoPharm ·

2025/02/20

We take a deep look at the recently published, and guideline changing, AMPLIFY trial of fixed-duration acalabrutinib in CLL.Link: DOI: 10.1056/NEJMoa2409804

en

00:12:35

OncoPharm M & M: Fatal TLS & Fatal T-cell lymphoma...

OncoPharm ·

2025/02/13

Morbidity & Mortality (M & M) are common case conferences to learn from unfortunate cases to improve care in the future. This episode looks at two recently published case reports.1. Fatal tumor lysis syndrome following a lack of venetoclax ramp-up in AML: https://www.jhoponline.com/issue-archive/2024-issues/december-2024-vol-14-no-6/rapid-onset-of-fatal-tumor-lysis-syndrome-in-a-patient-with-acute-myeloid-leukemia-receiving-azacitidine-and-venetoclax-without-a-ramp-up-schedule-a-case-report 2

en

00:18:34

[Re-release] Rituximab

OncoPharm ·

2025/02/06

Dipping into the archives (technology issues with new computer) to re-release the Foundations of OncoPharm episode on rituximab. Where did that 375 mg/m2 dose come from anyway?

en

00:08:47

Acalabrutinb + BR and sotorasib + panitumumab

OncoPharm ·

2025/01/30

FDA approves two new treatment regimens:1. Acalabrutinib + BR for untreated mantle cell lymphoma patients deemed ineligible for autologous HSCT 2. Sotorasib + panitumumab for KRAS-G12C mutated metastatic colorectal cancer (after chemotherapy, including oxaliplatin and irinotecan)

en

00:18:49

Datoptamab deruxtecan

OncoPharm ·

2025/01/22

Datopotamab deruxtecan, a newly approved agent for breast cancer, is discussed.

en

00:12:17

Dex Dosing in MM, Tec-Tal, & postMONARCH

OncoPharm ·

2025/01/16

HOPA Pharmacy Outcomes & Practice-Based Collaboration Survey: https://www.surveymonkey.com/r/MXNVRBRDexamethasone Dosing Intensity in Multiple Myeloma: https://doi.org/10.1182/blood.2024025939 Talquetamab + Teclistamab: https://doi.org/10.1182/blood.2024025939 postMONARCH: https://doi.org/10.1200/JCO-24-02086

en

00:10:52

Breakwater, Ensartinib, & SC Nivo

OncoPharm ·

2025/01/09

We discuss recent approvals of ensartinib and nivolumab-hyaluronidase as well as new front-line option for BRAV-V600E mutated metastatic colorectal cancer.

en

420 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter